3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Head & Neck
3
Sarcoma
2
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Docetaxel
7
Trastuzumab
3
sargramostim
2
entrectinib
2
Radiotherapy
2
Polymerase Chain Reaction
2
Immunohistochemistry
2
Gene Expression Profiling
2
Fluorodeoxyglucose F18
2
Flow Cytometry
2
Erlotinib Hydrochloride
2
Biopsy
2
zanidatamab
1
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
tipifarnib
1
tanespimycin
1
pertuzumab
1
pembrolizumab
1
oncogene protein E7, Human papillomavirus type 16
1
entinostat
1
alectinib
1
aldesleukin
1
X-Ray Therapy
1
Vorinostat
1
Thalidomide
1
Taxes
1
Ritonavir
1
Quality of Life
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
trastuzumab deruxtecan
×
Genitourinary
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled